Previous 10 | Next 10 |
In my 2020 outlook, which was pre-coronavirus, I argued the case for buying small and microcap medical stocks that were priced for "non-success". This approach worked in 2020. My 2020 themes were gene therapy, targeted oncologics, and less invasive surgery. For 2021, I add SARS CoV-2 ...
The 62nd ASH Annual Meeting and Exposition held virtually this year from December 5-8, 2020, has highlighted promising experimental therapies in biotech, enabling their developers to fortify their balance sheets through secondary offers as investors pore through the trial data.Since November ...
Palm Beach, FL –December 9, 2020 – In the breast cancer therapy market, the rise in the healthcare awareness among individual’s disease and treatment, early detection of the cancer, better surgical and medical treatment, R&D initiatives, and technological advancemen...
The following slide deck was published by IGM Biosciences, Inc. in conjunction with this event. For further details see: IGM Biosciences (IGMS) Presents At American Society of Hematology Meeting - Slideshow
IGM Biosciences (IGMS) has priced its upsized public offering of common shares at $90.00/share and pre-funded warrants to purchase shares of common stock at $89.99/pre-funded warrant, for expected total gross proceeds of ~$200M.Underwriters' over-allotment is an additional $30M of shares.IGM ...
MOUNTAIN VIEW, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) (IGM) today announced the pricing of its upsized underwritten public offering of shares of its common stock at a price to the public of $90.00 per share and, to certain investors in lieu of common ...
Gainers: Curis (CRIS) +335%.Lexicon Pharmaceuticals (LXRX) +97%.Mammoth Energy Services (TUSK) +61%.NeuroMetrix (NURO) +49%.Stitch Fix (SFIX) +45%.IGM Biosciences (IGMS) +38%.Blonder Tongue Laboratories (BDR) +26%.Infinity Pharmaceuticals (INFI) +25%.KLX Energy Services (KLXE) +24%....
IGM Biosciences (IGMS) to offer and sell $150M of shares in an underwritten public offering.Underwriters' option to purchase up to an additional $22.5M of shares.Actual size or terms of the offering not yet finalised.Press ReleasePreviously: IGM Biosciences stock jumps 19% after ASH pres...
MOUNTAIN VIEW, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced that it intends to offer and sell $150 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares...
IGM Biosciences (IGMS) climbs 19%, its biggest jump since February, after preliminary data from its Phase 1 trial evaluating IGM-2323 in non-Hodgkins lymphoma demonstrated tumor size reduction in nine of 14 patients.IGM-2323 is a bispecific IgM antibody targeting CD20 x CD3. The data was pres...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 5.6% to $127.4 on volume of 368,729,821 shares Maxeon Solar Technologies Ltd. (MAXN) rose 14.2% to $0.2407 on volume of 294,399,898 shares Kazia Therapeutics Limited (KZIA) rose 85.6% to $1.24 on volume ...
2024-05-31 20:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-24 12:15:03 ET RBC Capital analyst issues UNDERPERFORM recommendation for IGMS on May 24, 2024 10:00AM ET. The previous analyst recommendation was Underperform. IGMS was trading at $10.01 at issue of the analyst recommendation. The overall analyst consensus : BUY...